Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Buy" Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) in a research report report published on Wednesday morning,Benzinga reports.

Several other research firms have also recently issued reports on YMAB. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an "outperform" rating and a $23.00 price target on the stock. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a "strong-buy" rating in a research note on Tuesday, August 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Morgan Stanley dropped their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research report on Tuesday, August 13th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $20.89.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock traded down $0.27 during mid-day trading on Wednesday, reaching $10.01. 167,629 shares of the company were exchanged, compared to its average volume of 324,258. The firm's 50-day simple moving average is $13.12 and its two-hundred day simple moving average is $12.73. Y-mAbs Therapeutics has a twelve month low of $6.09 and a twelve month high of $20.90. The firm has a market cap of $448.35 million, a PE ratio of -19.04 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. As a group, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Insider Activity

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the firm's stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the sale, the insider now owns 97,681 shares of the company's stock, valued at approximately $1,315,763.07. This trade represents a 39.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth $44,000. China Universal Asset Management Co. Ltd. raised its stake in Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock valued at $113,000 after purchasing an additional 3,416 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Y-mAbs Therapeutics in the third quarter valued at approximately $133,000. SG Americas Securities LLC purchased a new position in shares of Y-mAbs Therapeutics during the third quarter worth approximately $178,000. Finally, Empire Financial Management Company LLC purchased a new position in shares of Y-mAbs Therapeutics during the third quarter worth approximately $210,000. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.